• Verapamil HCl in Osteoporosis and Inflammation Models: Advan

  2026-06-03

  Explore how Verapamil HCl, a leading L-type calcium channel blocker, advances translational research in osteoporosis and inflammatory disease models. This article uniquely deciphers recent mechanistic breakthroughs and assay implications for researchers.

• SZQ-3 Chromone-Maleimide Hybrid Prevents Osteoporosis via NF

  2026-06-03

  This study introduces SZQ-3, a synthetic chromone–maleimide hybrid, as a novel inhibitor of NF-κB that effectively prevents postmenopausal osteoporosis by targeting mitochondrial function in bone cells. The findings highlight SZQ-3's dual action in suppressing osteoblast apoptosis and osteoclast differentiation, paving the way for safer osteoporosis therapeutics.

• Tacalcitol Monohydrate Enhances 5-FU Sensitivity in CRC Cell

  2026-06-02

  The referenced study demonstrates that tacalcitol, a synthetic analog of vitamin D3, markedly increases the efficacy of 5-fluorouracil (5-FU) in colorectal cancer cells by downregulating thymidylate synthase via a vitamin D receptor-dependent pathway. These findings suggest a mechanistically grounded strategy to augment standard CRC chemotherapy while minimizing toxicity.

• CLCC1 Identified as Key Host Factor in Herpesvirus Nuclear E

  2026-06-02

  A recent study uncovers the essential role of the host chloride channel CLCC1 in mediating membrane fusion during herpesvirus nuclear egress. By employing a genome-wide CRISPR screen, the authors reveal how CLCC1 loss disrupts viral capsid export and reduces viral titers, providing mechanistic insight relevant for antiviral strategies and immunomodulatory research.

• (S)-(+)-Ibuprofen: Precision Modulation of Inflammation Path

  2026-06-01

  (S)-(+)-Ibuprofen enables advanced, precise control of inflammation pathways for researchers investigating COX inhibition and prostaglandin synthesis suppression. This article offers a uniquely practical and mechanistic perspective, integrating assay guidance, the latest synthetic advances, and critical differentiation from existing thought-leadership content.

• RapaLink-1: Third-Generation mTOR Inhibitor for Dormancy & O

  2026-06-01

  RapaLink-1, a third-generation mTOR inhibitor from APExBIO, unlocks robust, reversible control of cell proliferation and dormancy across cancer and stem cell models. Its unique bivalent mechanism enables researchers to overcome resistance and elevate reproducibility in both tumor regression and embryonic diapause protocols.

• Targeted Non-Viral Gene Delivery to Adipocytes via ATS-9R

  2026-05-31

  The reference study introduces ATS-9R, a fusion oligopeptide that enables selective, non-viral gene delivery to mature adipocytes through prohibitin-mediated endocytosis. This innovation overcomes longstanding transfection barriers in adipocyte biology and demonstrates metabolic improvement and weight reduction in obese mouse models, offering a promising platform for precise gene silencing in obesity research.

• Oxaliplatin (SKU A8648): Reliable Solutions for Cancer Assay

  2026-05-30

  This article addresses core laboratory challenges in cell viability, cytotoxicity, and apoptosis assays, using Oxaliplatin (SKU A8648) as a reference platinum-based chemotherapeutic agent. Grounded in quantitative data and recent literature, it delivers scenario-driven guidance for experimental reproducibility, resistance modeling, and practical vendor selection. Readers will find actionable insights and protocol parameters for optimizing their cancer research workflows.

• ATRX Loss Sensitizes High-Grade Glioma to RTK/PDGFR Inhibito

  2026-05-29

  The reference study demonstrates that ATRX-deficient high-grade glioma cells are significantly more sensitive to multi-targeted receptor tyrosine kinase (RTK) and PDGFR inhibitors. This finding suggests ATRX status could serve as a predictive biomarker for targeted therapy response and inform clinical trial design in aggressive gliomas.

• Palonosetron Hydrochloride in CINV Prevention: Mechanisms an

  2026-05-29

  The reference study by Ruhlmann and Herrstedt provides a detailed evaluation of palonosetron hydrochloride as an advanced 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting (CINV). The paper's innovation lies in its focus on the unique pharmacologic properties and clinical advantages of palonosetron, particularly in the delayed phase of CINV, highlighting its implications for antiemetic therapy design.

• D-Luciferin Potassium Salt: Precision for In Vivo Imaging &

  2026-05-28

  D-Luciferin (potassium salt) empowers researchers with superior water solubility and purity, streamlining both in vivo bioluminescence imaging and high-throughput in vitro assays. Its robust performance enables sensitive tumor cell tracking and real-time disease monitoring, offering clear differentiation from conventional substrates.

• Artesunate: Optimizing In Vitro Cancer Research Workflows

  2026-05-28

  Artesunate, an advanced artemisinin derivative, empowers oncology labs to dissect cancer cell death mechanisms with precision. This guide bridges bench research and protocol innovation, highlighting stepwise workflows and troubleshooting strategies for reproducible results in small cell lung and esophageal squamous cell carcinoma models.

• Phillygenin Attenuates Diabetic Nephropathy via Inflammation

  2026-05-27

  This study demonstrates that phillygenin, a Forsythia suspensa–derived compound, mitigates diabetic nephropathy by inhibiting inflammation and apoptosis through modulation of TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β signaling. The findings highlight phillygenin's potential as a novel therapeutic candidate targeting the molecular drivers of diabetic kidney injury.

• Tacalcitol Monohydrate Sensitizes CRC Cells to 5-FU via TS D

  2026-05-27

  The referenced study demonstrates that tacalcitol monohydrate, a synthetic analog of vitamin D3, enhances the effectiveness of 5-fluorouracil (5-FU) against colorectal cancer (CRC) cells by downregulating thymidylate synthase through vitamin D receptor signaling. These findings suggest a mechanistic basis for combining vitamin D analogs with standard chemotherapy to improve CRC treatment outcomes.

• Veratridine: Voltage-Gated Sodium Channel Opener in Research

  2026-05-26

  Veratridine stands out as a precision voltage-gated sodium channel opener, enabling high-resolution studies in neurophysiology, excitotoxicity, and cancer modulation. APExBIO’s validated Veratridine (CAS 71-62-5) streamlines workflows from sodium channel dynamics research to advanced screening assays, with robust troubleshooting guidance for reproducible results.

408 records 13/28 page Previous Next First page 上5页 1112131415 下5页 Last page